Biodegradable nanoparticles as novel hemoglobin-based oxygen carriers and methods of using the same
Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.
1. An oxygen carrier composition, comprising:
a polymersome comprising a plurality of block copolymer chains, wherein each block copolymer chain comprises:
at least one hydrophilic polymer block; and
at least one hydrophobic polymer block;
an oxygen-binding compound containing a heme group; and
an oxidation-suppressing agent,
wherein the oxygen-binding compound and the oxidation-suppressing agent are co-encapsulated within an aqueous core of the polymersome, and wherein the oxidation-suppressing agent limits oxidation of the heme group during formation of the oxygen carrier composition.
2. The composition of claim 1 , wherein the oxygen-binding compound comprises a naturally occurring protein, a recombinant protein, a recombinant polypeptide, a synthetic polypeptide, a chemical synthesized by an animal, a synthetic small molecule, a carbohydrate, a nucleic acid, a lipid or a polymer.
3. The composition of claim 1 , wherein the oxygen-binding compound comprises hemoglobin or a derivative of hemoglobin.
4. The composition of claim 1 , wherein at least one polymer block in each of the plurality of block copolymer chains is a biodegradable polymer, and at least one polymer block in each of the plurality of block copolymer chains of polymers is a biocompatible polymer.
5. The composition of claim 4 , wherein the biodegradable polymer is selected from the group of poly(ε-caprolactone) and poly(γ-methyl ε-caprolactone).
6. The composition of claim 4 , wherein the biocompatible polymer is selected from the group of poly(ethylene oxide) and poly(ethylene glycol).
7. The composition of claim 4 , wherein the at least one hydrophobic block comprises poly(ethylene oxide), wherein the hydrophobic block comprises poly(ε-caprolactone).
8. The composition of claim 1 , wherein the at least one hydrophobic block comprises poly(ε-caprolactone) having a number-average molecular weight between about 9 kilodaltons and about 23 kilodaltons.
9. The composition of claim 1 , wherein the plurality of block copolymer chains includes at least one diblock copolymer, wherein the at least one hydrophobic block of the diblock copolymer comprises polycaprolactone having a number-average molecular weight between about 4 kilodaltons and about 10 kilodaltons.
10. The composition of claim 1 , wherein the at least one hydrophilic block comprises poly(ethylene oxide) having a number-average molecular weight between about 1.8 kilodaltons and about 2 kilodaltons, and wherein the poly(ε-caprolactone) has a number-average molecular weight of between about 8 kilodaltons and about 12 kilodaltons.
11. The composition of claim 1 , wherein the polymersome comprises a hydrophobic membrane, and wherein a ligand is conjugated to a polymersome surface.
12. The composition of claim 1 , further comprising at least one allosteric effector encapsulated within the polymersome, wherein the allosteric effector is a naturally occurring molecule, a recombinant molecule, a synthetic molecule or a polymer.
13. The composition of claim 11 , wherein the allosteric effector modifies oxygen-binding through hydrogen ions, carbon dioxide, or 2,3-bisphosphoglycerate.
14. The composition of claim 1 , further comprising at least one pharmaceutically active agent encapsulated within the polymersome.
15. The composition of claim 1 , wherein the polymersome has a hydrophilic surface.
16. The composition of claim 15 , further comprising a pharmaceutically active agent covalently linked to the hydrophilic surface of the polymersome.
17. The composition of claim 15 , further comprising an allosteric effector covalently linked to the hydrophilic surface of the polymersome, wherein the allosteric effector is a naturally occurring molecule, a recombinant molecule, a synthetic molecule or a polymer.
18. The composition of claim 15 , wherein the allosteric effector modifies oxygen-binding through hydrogen ions, carbon dioxide, or 2,3-bisphosphoglycerate.
19. The composition of claim 1 , wherein the polymersome has a diameter of between about 50 nm and about 5 μm, and has a membrane thickness between about 5 nm and about 30 nm.
20. The composition of claim 1 , wherein two or more of the multiblock copolymer chains are covalently bonded to one another.
21. The composition of claim 1 , wherein the multiblock copolymer chains comprise a bilayer structure.
22. The composition of claim 1 , wherein the at least one hydrophilic block polymer is selected from the group of poly(ethylene oxide), poly(acrylic acid), poly(ethylene glycol), and polyvinyl alcohol.
23. The composition of claim 1 , wherein the at least one hydrophobic block polymer is selected from the group of poly(caprolactone), poly(methylcaprolactone), poly(menthide), poly(lactide), poly(glycolide), poly(methylglycolide), poly(dimethylsiloxane), poly(isobutylene), poly(styrene), poly(ethylene), and polypropylene oxide).
24. The composition of claim 1 , wherein the plurality of block copolymer chains includes at least one triblock copolymer comprising at least one biocompatible polymer and at least one biodegradable polymer.
25. The composition of claim 24 , wherein the at least one biocompatible polymer is selected from the group of poly(ethylene oxide) and poly(ethylene glycol), and wherein the at least one biodegradable polymer is selected from at least one of poly(ε-caprolactone) and poly(γ-methyl ε-caprolactone).
26. The composition of claim 1 , wherein the plurality of block copolymer chains includes at least a first diblock copolymer comprising first hydrophilic and hydrophobic blocks, and a second diblock copolymer comprising second hydrophilic and hydrophobic blocks, wherein:
at least one of the hydrophilic and hydrophobic blocks comprises a mixture of different polymers.
27. A method of treating a subject, comprising:
administering to the subject an oxygen carrier composition comprising:
a polymersome that includes a plurality of block copolymer chains, wherein each block copolymer chain comprises at least one hydrophilic polymer block and at least one hydrophobic polymer block;
an oxygen-binding compound containing a heme group; and
an oxidation-suppressing agent, wherein:
the oxygen-binding compound and the oxidation-suppressing agent are co-encapsulated within an aqueous core of the polymersome; and
the oxidation-suppressing agent limits oxidation of the heme group during formation of the oxygen carrier composition;
wherein the oxygen carrier is administered intravenously, via inhalation, topically, per rectum, per the vagina, transdermally, subcutaneously, intraperitoneally, intrathecally, intramuscularly, or orally.
28. A kit, comprising:
a pharmaceutical composition comprising an oxygen carrier, wherein the oxygen carrier comprises:
a polymersome that comprises a plurality of block copolymer chains, wherein each block copolymer chain comprises at least one hydrophilic polymer block and at least one hydrophobic polymer block;
an oxygen-binding compound containing a heme group; and
an oxidation-suppressing agent,
wherein the oxygen-binding compound and the oxidation-suppressing agent are co-encapsulated within an aqueous core of the polymersome, and wherein the oxidation-suppressing agent limits oxidation of the heme group during formation of the oxygen carrier composition; and
an implement for administering the oxygen carrier intravenously, via inhalation, topically, per rectum, per the vagina, transdermally, subcutaneously, intraperitoneally, intrathecally, intramuscularly, or orally.